(Q36945032)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17877447%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

review article

1 reference

title

Paclitaxel: a review of adverse toxicities and novel delivery strategies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17877447%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17877447%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

6

Henry Brem

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17877447%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

James E Han

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17877447%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Khan W Li

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17877447%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Violette M Renard

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17877447%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Betty M Tyler

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17877447%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

language of work or name

English

0 references

publication date

1 September 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17877447%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Safety

7 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17877447%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17877447%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17877447%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

609-621

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17877447%20AND%20SRC:MED&resulttype=core&format=json

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Enhanced taxol production and release in Taxus chinensis cell suspension cultures with selected organic solvents and sucrose feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Enhancement of Taxol production and excretion in Taxus chinensis cell culture by fungal elicitation and medium renewal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Stimulation of taxol production and excretion in Taxus spp cell cultures by rare earth chemical lanthanum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Production of paclitaxel and the related taxanes by cell suspension cultures of Taxus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

The taxol supply crisis. New NCI policies for handling the large-scale production of novel natural product anticancer and anti-HIV agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Promotion of microtubule assembly in vitro by taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Structure of the alpha beta tubulin dimer by electron crystallography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Structure of tubulin at 6.5 A and location of the taxol-binding site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Taxol stabilizes microtubules in mouse fibroblast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Taxol binds to cellular microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Microtubule-targeted anticancer agents and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Taxol induces tyrosine phosphorylation of Shc and its association with Grb2 in murine RAW 264.7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Induction of expression of inducible nitric oxide synthase by Taxol in murine macrophage cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

The role of MAPK pathways in the action of chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Taxol induces caspase-10-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Clinical pharmacokinetics of paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Hypersensitivity reactions from taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Stimulation of Erythrocyte Phosphatidylserine Exposure by Paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Paclitaxel: as adjuvant or neoadjuvant therapy in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Phase I trial of weekly paclitaxel in advanced lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Recent advances in drug-induced neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Managing the neurotoxicity of paclitaxel (Taxol) and docetaxel (Taxotere) with neurotrophic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Calpain inhibition protects against Taxol-induced sensory neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Taxol: a novel investigational antimicrotubule agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Tumour-host metabolic interrelationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

The effect of omega-6 and omega-3 fatty acids on 3H-thymidine incorporation in hepatoma 7288CTC perfused in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Poly(L-glutamic acid)--anticancer drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Thermosensitive chitosan-based hydrogel containing liposomes for the delivery of hydrophilic molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Local intracerebral administration of Paclitaxel with the paclimer delivery system: toxicity study in a canine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Advancing the field of drug delivery: taking aim at cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

In vivo delivery of BCNU from a MEMS device to a tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

In vivo release from a drug delivery MEMS device

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Multi-pulse drug delivery from a resorbable polymeric microchip device.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

Targeted therapy for brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.609

21 January 2018

Identifiers

DOI

10.1517/14740338.6.5.609

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17877447%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference